Clinical Trials on Diabetes+Mellitus

Total 20055 results

The Third Xiangya Hospital of Central South University

Completed

Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan

Type 2 Diabetic Nephropathy

China
Centro Universitario de Ciencias de la Salud, Mexico

Unknown

Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy

Diabetic Nephropathy Type 2

Mexico
Marashi Eye Clinic

Completed

PRP vs Bevacizumab for PDR Treatment

Proliferative Diabetic Retinopathy

Syrian Arab Republic
Kyorin University

Completed

Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy

Japan
Anders Kvanta

Completed

Vitrous Analysis in Proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy

Sweden
Kyorin University

Completed

Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy

Japan
Pamlab, L.L.C.
HealthCore, Inc.

Completed

Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy (DPN)

United States
Cairo University

Completed

Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease

Proliferative Diabetic Retinopathy

Egypt
University of Campania "Luigi Vanvitelli"
Napoli CTO Hospital

Completed

Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy
National Taiwan University Hospital

Completed

Macular Appearance After Diabetic Vitrectomy

Proliferative Diabetic Retinopathy | Vitrectomy

Taiwan
Retina Associates, Kansas City
Genentech, Inc.

Unknown

Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

Proliferative Diabetic Retinopathy

United States
Eli Lilly and Company

Completed

Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain

Diabetic Neuropathy, Painful

United States, Puerto Rico
University of Campania "Luigi Vanvitelli"

Recruiting

Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA) (GIOIA)

Type 2 Diabetes Mellitus

Italy
Population Health Research Institute
Novo Nordisk A/S

Completed

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (REMITiDegLira)

Type 2 Diabetes Mellitus

Canada
Northwell Health
Patient-Centered Outcomes Research Institute

Completed

Diabetes Management Program for Hispanic/Latino

Type 2 Diabetes Mellitus | Type 2 Diabetes

United States
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes (AWARD-CHN3)

Type 2 Diabetes Mellitus

China
University of Minnesota
University of Southern California; Wake Forest University

Completed

The Long-term Effects of an Intensive Lifestyle Intervention for Type 2 Diabetes on Medicare Outcomes

Type 2 Diabetes Mellitus
Joslin Diabetes Center
DHR Health Institute for Research and Development; Verizon Foundation

Completed

Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With T2 Diabetes

Type 2 Diabetes Mellitus

United States
Pendulum Therapeutics

Terminated

Placebo-Controlled Clinical Nutrition Study of the Metabolic Effects of Food Product WBF-0011 in Type 2 Diabetes

Type 2 Diabetes Mellitus

Ireland
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

Type 2 Diabetes Mellitus

Russian Federation, United States, Puerto Rico, Australia, Taiwan, Israel, Spain, Canada, Greece, Argentina, Poland, Romania, Mexico, Slovakia, Brazil
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes (SURPASS-3)

Type 2 Diabetes Mellitus

United States, Korea, Republic of, Taiwan, Italy, Austria, Puerto Rico, Hungary, Greece, Poland, Spain, Romania, Ukraine, Argentina
Marja-Riitta Taskinen
Göteborg University

Completed

Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

Type 2 Diabetes Mellitus

Finland
University of California, San Francisco
National Center for Complementary and Integrative Health (NCCIH)

Completed

(R33 Phase) Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger (Delish R33)

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

Diabetes | Type 2 Diabetes Mellitus

Germany
Massachusetts General Hospital

Completed

A Psychological-behavioral Intervention to Increase Activity in Type 2 Diabetes (BEHOLD-16)

Type 2 Diabetes Mellitus

United States
Karolinska Institutet

Completed

Glycemic Control and Endothelial Function in Patients With Type 2 Diabetes (AIDdiabetes)

Type 2 Diabetes Mellitus

Sweden
Evidation Health
One Drop

Completed

One Drop Experts Program for Type 2 Diabetes Self-Management: Impact on A1c

Type 2 Diabetes Mellitus

United States
Massachusetts General Hospital

Completed

The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes (SPT2D)

Type 2 Diabetes Mellitus

United States
Shanghai Jiao Tong University Affiliated Sixth...

Completed

The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Beth Israel Deaconess Medical Center
Boston University; Peking University; University of Washington; University of Massachusetts... and other collaborators

Completed

Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Type 2 Diabetes Mellitus

Japan
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)

Type 2 Diabetes Mellitus
All India Institute of Medical Sciences, Bhubaneswar
Chemical Resources

Completed

Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes

Type-2 Diabetes Mellitus

India
Adocia

Completed

A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
University of Michigan
Mahidol University; Fogarty International Center of the National Institute...

Completed

The Adaptation, Usability, and Feasibility of a Mobile Health (mHealth) System to Improve Type 2 Diabetes Self-management in Thailand

Type 2 Diabetes Mellitus

Thailand
Merck Sharp & Dohme LLC

Completed

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Type 2 Diabetes Mellitus
AstraZeneca

Completed

Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin. (REALITY)

Type 2 Diabetes Mellitus

Bulgaria
Sanofi

Completed

Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

Type 2 Diabetes Mellitus

Germany
Sanofi

Completed

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)

Type 2 Diabetes Mellitus

United States, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, South Africa, Swed... and more
Merck Sharp & Dohme LLC
Bristol-Myers Squibb

Terminated

An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)

Type 2 Diabetes Mellitus
VeroScience

Completed

Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes

Type 2 Diabetes Mellitus
Sanofi

Completed

Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

Type 2 Diabetes Mellitus

Russian Federation
Laval University
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes (JANUB48)

Type 2 Diabetes Mellitus

Canada
Takeda

Terminated

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes (GRAND-307)

Type 2 Diabetes Mellitus

Taiwan, China, Korea, Republic of, New Zealand, Australia
AstraZeneca

Completed

Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus (DURATION-NEO-2)

Diabetes Type 2

United States
Sanofi

Completed

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Merck Sharp & Dohme LLC

Completed

A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)

Type 2 Diabetes Mellitus
AstraZeneca

Completed

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin

Type 2 Diabetes Mellitus

Korea, Republic of, Mexico, Germany, Greece, Argentina, India, Australia
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Type 2 Diabetes Mellitus

United States, Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Turkey, United Kingdom, South Africa, Argentina, Canada, Germany, Hungary, Israel, Romania, Slovakia, India, Belgium, France, Puerto Rico

3

Subscribe